But Paul Grootendorst, an associate professor at the University of Toronto’s Leslie Dan School of Pharmacy, says setting up such a company would be more problematic than it’s worth. In an article titled “Home Remedies: How Should Canada Acquire Vaccines for the Next Pandemic?”Recently published through the CDHowe Institute, Grootendorst and his co-authors are exploring other tactics for Canada to better stimulate vaccine production ahead of the next pandemic.
Grootendorst wrote the paper with Michael Schunk and Robert Van Exan, independent experts in the vaccine industry, and Javad Moradpour, a postdoctoral fellow at the Leslie Dan School of Pharmacy.
“Vaccine production is very confusing and time-consuming. In the pipeline, other vaccines require other production platforms and it is unclear what platform will be needed for the next pandemic vaccine,” says Grootendorst. “In this analysis, we looked to upload another one that would highlight the complexity of the issue. “
The researchers describe how the high failure rates of vaccine candidates and the logistics involved in a giant clinical trial, especially one that wants to be conducted quickly, would make vaccine progression a costly task for a public framework, with a significant threat that no viable vaccine will be. Candidate would provide himself.
Even if the company focused only on licensing and generating an evolved pandemic vaccine elsewhere, it would be complicated for a committed pandemic vaccine facility in a position for production with the required expertise and lines of origin, according to the authors.
“You can’t turn on a production facility at will, and it’s difficult to temporarily move into vaccine production,” says grotendorst. in commercial-scale production and doing clinical trials. “
Instead, the researchers recommend hiring “academic and advertising actors” who already possess the expertise and technical capacity to produce vaccines on a large scale. vaccine production. Domestic suppliers would make a stockpile of the vaccines they normally manufacture in the event of an emergency.
Grootendorst and his co-authors also claim that the Canadian government can simply build modular production services that can be temporarily adapted to make a vaccine opposed to a new virus. These services “would be on the ground of an established vaccine manufacturer and would take advantage of the manufacturer’s sterilized water, gas, steam, ventilation, waste disposal, and other services/infrastructure,” the document says.
While new variants of the COVID-19 pandemic continue to circulate, Grootendorst says it’s vital to start preparing for the next pandemic, as vaccine production requires long lead times and viral outbreaks appear to be more frequent.
Between 1918 and 2000, there were 4 major epidemics and pandemics, the researchers note; since 2000, there have already been six “primary viral epidemics. “
Please indicate the appropriate maximum category to facilitate the processing of your application
Thank you for taking the time to provide your feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.